BIOCON SDN. BHD.

Biocon and Duopharma Biotech Secure Over MYR 225 Million in Insulin Contracts from Malaysia's Ministry of Health

- Biocon's partner Duopharma Biotech secured multiple insulin contracts from Malaysia's Ministry of Health valued at over MYR 225 million. - The contracts cover short-acting recombinant human insulin, insulin glargine, and insulin aspart, with agreements spanning two to three years. - Biocon's Johor facility, Asia's largest integrated insulin manufacturing plant, will supply the products, supporting over 450,000 patients in Malaysia's public healthcare system. - An estimated 4.75 million people live with diabetes in Malaysia, underscoring the critical need for affordable and accessible insulin therapies.